ValuEngine cut shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) from a hold rating to a sell rating in a research note published on Friday.

Separately, Maxim Group set a $10.00 target price on shares of Sonoma Pharmaceuticals and gave the company a buy rating in a research note on Wednesday, August 9th.

Sonoma Pharmaceuticals (NASDAQ SNOA) opened at 5.68 on Friday. Sonoma Pharmaceuticals has a 1-year low of $3.91 and a 1-year high of $8.25. The firm has a 50-day moving average of $6.18 and a 200-day moving average of $6.73. The firm has a market capitalization of $24.46 million, a price-to-earnings ratio of 2.90 and a beta of 1.28.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last released its earnings results on Tuesday, August 8th. The company reported ($0.82) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.73) by $0.09. The company had revenue of $3.84 million for the quarter. Sonoma Pharmaceuticals had a net margin of 54.36% and a negative return on equity of 44.24%. On average, analysts expect that Sonoma Pharmaceuticals will post ($2.67) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This report was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The correct version of this report can be viewed at

A hedge fund recently raised its stake in Sonoma Pharmaceuticals stock. Janus Capital Management LLC grew its holdings in shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) by 41.1% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 37,926 shares of the company’s stock after purchasing an additional 11,053 shares during the period. Janus Capital Management LLC owned approximately 0.89% of Sonoma Pharmaceuticals worth $272,000 as of its most recent filing with the Securities and Exchange Commission. 9.78% of the stock is owned by institutional investors.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc, formerly Oculus Innovative Sciences, Inc, is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The Company’s product portfolio consists of dermatology and advanced tissue care products based upon its technologies, such as Microcyn and Lipogrid.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Stock Ratings for Sonoma Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.